CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma |
| January 08, 2020 | January 2020 Bond Updates |
|
SUZHOU, China, Jan. 8, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) announced that the first patient has been dosed in the Phase III GEMSTONE-304 study of the Company's anti-PD-L1 antibody CS1001 in combination therapy as first-line treatment in... |
| View more at: https://www.prnewswire.com:443/news-releases/cstone-announces-first-patient-dosed-in-the-phase-iii-trial-of-cs1001-in-combination-with-chemotherapy-in-first-line-esophageal-squamous-cell-carcinoma-300983342.html |
| Related News |